刘美 高金娥

    【摘要】 冠状动脉粥样硬化性心脏病(CHD)，是由脂质代谢紊乱和慢性炎症性疾病导致冠状动脉病理改变的一类疾病，中老年人群中较常见，由多种炎症因子共同参与其发生发展，在心血管(CV)疾病中发病率和死亡率占重要比例。临床上对冠心病的相关诊断有着较多的检测指标，脂蛋白相关磷脂酶A2(Lp-PLA2)就是最重要的一种，它对整个生命周期中的心脏症状、治疗和干预以及日常生活的影响和长期健康的评估都非常重要。本文拟Lp-PLA2在冠心病中的发展做一综述。

    【关键词】 磷脂酶A2 冠心病 Darapladib

    Research Progress of Lipoprotein Associated Phospholipase A2 and Coronary Heart Disease/LIU Mei， GAO Jin’e. //Medical Innovation of China， 2022， 19(12)： -188

    [Abstract] Coronary atherosclerotic heart disease (CHD)， it is a kind of coronary artery disease caused by lipid metabolism disorder and chronic inflammatory disease， it is common in middle-aged and elderly people， and is involved in the occurrence and development of multiple inflammatory factors， accounting for an important proportion of the morbidity and mortality of cardiovascular (CV) diseases. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is one of the most important indicators in clinical diagnosis of coronary heart disease， it is very important for cardiac symptoms， treatment and intervention throughout the life cycle， as well as the impact of daily life and long-term health assessment. This article reviews the development of Lp-PLA2 in coronary heart disease. ......